Guided Therapeutics Announces 1:800 Reverse Stock Split and Elimination of “Toxic” Convertible Securities from its Balance Sheet

Guided Therapeutics Receives Order for 7 LuViva® Advanced Cervical Scans and 4,000 Disposable Cervical Guides for Indonesia

Guided Therapeutics Reports Second Quarter 2016 Financial Results; Year to Date Revenue Up 71% Over Same Period Last Year

Guided Therapeutics Ships Additional LuViva® Advanced Cervical Scan Systems and Disposables to Bangladesh

Guided Therapeutics Sells First LuViva® Advanced Cervical Scan to Russia

Guided Therapeutics Ships Five LuViva® Advanced Cervical Scans to Nairobi County, Kenya for Cervical Cancer Screening Program

Guided Therapeutics Expanding Use of the LuViva® Advanced Cervical Scan in Bulgaria

Guided Therapeutics Enters into LuViva® Advanced Cervical Scan License Agreement for China

Guided Therapeutics Reports Record First Quarter 2016 Results

Guided Therapeutics Ships First LuViva® Advanced Cervical Scan for the Dominican Republic

Guided Therapeutics Issues Letter to Shareholders

Guided Therapeutics Shipping Largest Order to Date of LuViva® Advanced Cervical Scan Single-Patient-Use Disposables

Guided Therapeutics Reports 2015 Results With Strong Uptick in Fourth Quarter

Guided Therapeutics’ LuViva® Advanced Cervical Scan Gaining Traction in the Middle East

Guided Therapeutics Schedules Conference Call to Discuss Fourth Quarter 2015 Financial Results

Guided Therapeutics Targeting Large Cervical Cancer Screening Markets with LuViva® Advanced Cervical Scan with New Single-Patient-Use Disposable

Guided Therapeutics Announces 1:100 Reverse Stock Split

Guided Therapeutics Expands LuViva® Advanced Cervical Scan Distribution in Latin America

Guided Therapeutics’ to Sell Five Additional LuViva® Advanced Cervical Scans to Nairobi County, Kenya for Cervical Cancer Screening Program

Guided Therapeutics Expects Significant Sales Growth in 2016

Guided Therapeutics Achieves Record Quarterly Revenue

Company Profile for Guided Therapeutics, Inc.